Earnings Summary

United Therapeutics Corporation’s revenue jumped 27.76% since last year same period to $596.5Mn in the Q2 2023. On a quarterly growth basis, United Therapeutics Corporation has generated 17.68% jump in its revenue since last 3-months.

United Therapeutics Corporation’s net profit jumped 123.45% since last year same period to $259.2Mn in the Q2 2023. On a quarterly growth basis, United Therapeutics Corporation has generated 7.6% jump in its net profits since last 3-months.

United Therapeutics Corporation’s net profit margin jumped 74.9% since last year same period to 43.45% in the Q2 2023. On a quarterly growth basis, United Therapeutics Corporation has generated -8.57% fall in its net profit margins since last 3-months.

United Therapeutics Corporation’s earning per share (EPS) estimates for the current quarter stand at 4.51 - a 15.94% jump from last quarter’s estimates.

United Therapeutics Corporation’s earning per share (EPS) estimates for the current year stand at 4.51.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. United Therapeutics Corporation’s return on assets (ROA) stands at 0.11.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. United Therapeutics Corporation’s return on equity (ROE) stands at 0.18.